Positive real-world data on pitolisant in narcolepsy

USA-based Harmony Biosciences, a part of the Paragon Biosciences corporate family, presented encouraging new data on its investigational drug pitolisant at the 7th International Symposium on Narcolepsy.

Pitolisant that has been studied for the treatment of both excessive daytime sleepiness (EDS) and cataplexy in adult patients with narcolepsy.

These long term data (up to 5-years) from the Harmony III open-label, naturalistic study assessed the safety, tolerability and durability of effect of pitolisant, the first potent and highly selective histamine 3 (H3) receptor antagonist/inverse agonist. If approved, pitolisant would represent the first new therapy in the USA in over a decade for the treatment of both EDS and cataplexy in patients with narcolepsy.